PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects
Publication
, Conference
DePaoli, A; Bashir, M; Phung, V; Yan, A; Ling, L; Baxter, B; Tian, H
Published in: Journal of Hepatology
April 2019
Duke Scholars
Published In
Journal of Hepatology
DOI
ISSN
0168-8278
Publication Date
April 2019
Volume
70
Issue
1
Start / End Page
e68 / e69
Publisher
Elsevier BV
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
DePaoli, A., Bashir, M., Phung, V., Yan, A., Ling, L., Baxter, B., & Tian, H. (2019). PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects. In Journal of Hepatology (Vol. 70, pp. e68–e69). Elsevier BV. https://doi.org/10.1016/s0618-8278(19)30120-3
DePaoli, Alex, Mustafa Bashir, Van Phung, Andrew Yan, Lei Ling, Bryan Baxter, and Hui Tian. “PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects.” In Journal of Hepatology, 70:e68–69. Elsevier BV, 2019. https://doi.org/10.1016/s0618-8278(19)30120-3.
DePaoli A, Bashir M, Phung V, Yan A, Ling L, Baxter B, et al. PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects. In: Journal of Hepatology. Elsevier BV; 2019. p. e68–9.
DePaoli, Alex, et al. “PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects.” Journal of Hepatology, vol. 70, no. 1, Elsevier BV, 2019, pp. e68–69. Crossref, doi:10.1016/s0618-8278(19)30120-3.
DePaoli A, Bashir M, Phung V, Yan A, Ling L, Baxter B, Tian H. PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects. Journal of Hepatology. Elsevier BV; 2019. p. e68–e69.
Published In
Journal of Hepatology
DOI
ISSN
0168-8278
Publication Date
April 2019
Volume
70
Issue
1
Start / End Page
e68 / e69
Publisher
Elsevier BV
Related Subject Headings
- Gastroenterology & Hepatology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences